MedPath

Pharmacokinetic-Pharmacodynamic Relationship of Metformin in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Registration Number
NCT02712619
Lead Sponsor
Seoul National University Hospital
Brief Summary

Two doses of metformin with 12 hour interval

* low dose group (375/250 mg)

* high dose group (1000/1000mg)

Detailed Description

A study to evaluate and compare the pharmacokinetic-pharmacodynamic relationship between different metformin dose groups.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
20
Inclusion Criteria
  • Age 20 to 45
  • Body weight 50 to 100 kg
  • fasting serum glucose 70 to 125 mg/dL
  • who provide informed consent voluntarily
Read More
Exclusion Criteria
  • any significant renal, gastrointestinal, hepatic, and metabolic condition
  • any co/prior medication within 14 days of study drug administration
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
metformin 250mgMetforminmetformin 375/250 mg
metformin 1000mgMetforminmetformin 1000/1000 mg
Primary Outcome Measures
NameTimeMethod
Maximum plasma concentration0-12 hour
Area under the metformin concentration curve0-12 hour
Area under the glucose curve2-5 hour
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath